Dr. Warren and leads a team to leverages multiplexed, molecular profiling technologies to address key research areas in oncology, immunology, and beyond. She partners with academics, biopharmas, and clinicians to identify unmet needs in translational research, create novel products for transcriptional and proteomic profiling, and deploy those tools to advance scientific discovery. She is also active in the research community to promote the science and application of cancer immunotherapy to improve patient outcomes. She has authors more than 50 articles and book chapters in leading journals.
Ira Mellman, Genentech
Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance